

Update on Treatment Options for Leukemia: Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myelogenous Leukemia

Learning Objectives

- Outline the alterations in cytogenetic, molecular abnormalities, NOTCH1, CRLF2 mutations, epigenetic markers in the diagnosis and treatment of patients with acute lymphoblastic leukemia (ALL)
- Select the novel therapeutic options for adolescents and young adults (AYA) relapsed/refractory Philadelphia-positive and Philadelphia-negative patients with ALL
- Assess the prognostic markers, risk stratification and their impact on clinical practice of patients with chronic lymphocytic lymphoma (CLL)
- Identify and apply individualized treatment strategies based on current and emerging novel therapies for CLL
- Describe the alterations in driver mutations revealing molecular subgroups leading to disease classification and prognostic stratification in acute myeloid leukemia (AML)
- Recognize how compound genotypes are related to clinical outcomes in AML patients treated with novel agents
- Evaluate the first line therapy options for chronic myelogenous leukemia (CML) in chronic phase
- Identify response assessment and management of tyrosine kinase inhibitors resistance in the treatment of CML
- Cite treatment options for myelodysplastic syndromes